Managers’ transactions
(“Faron” or the “Company”)Company announcement, 8 July 2020 at 5 PM (EEST) TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces today that Mr Toni Hänninen, Chief Financial Officer of the Company, acquired 4,400 ordinary shares in Faron at a price of €3.510 per share on 8 July 2020. Following these purchases, Mr Hänninen holds 54,697 ordinary shares in the Company. The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.